These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 8831191)

  • 1. [In vitro activities of benzoxazinorifamycin KRM-1648 against Mycobacterium tuberculosis].
    Sato K; Tomioka H; Saito H; Kawahara S; Hidaka T
    Kekkaku; 1996 Aug; 71(8):459-64. PubMed ID: 8831191
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Studies on therapeutic efficacy of a new anti-tuberculous drug, benzoxazinorifamycin, against murine experimental mycobacterial infections: attempt at various regimens and protocols].
    Tomioka H; Saito H
    Kekkaku; 1994 Nov; 69(11):703-10. PubMed ID: 7837724
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro and in vivo activities of the benzoxazinorifamycin KRM-1648 against Mycobacterium tuberculosis.
    Hirata T; Saito H; Tomioka H; Sato K; Jidoi J; Hosoe K; Hidaka T
    Antimicrob Agents Chemother; 1995 Oct; 39(10):2295-303. PubMed ID: 8619585
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Therapeutic efficacy of benzoxazinorifamycin KRM-1648 against experimental murine tuberculosis: (1). A study on the efficacy of short course treatment with the intratracheal and intravenous infection model].
    Doi N
    Kekkaku; 1998 Feb; 73(2):53-64. PubMed ID: 9545697
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [In vitro antimicrobial activities of quinolones, rifamycins and macrolides against Mycobacterium tuberculosis and M.avium complex: attempt to establish new assay methods which accurately reflect therapeutic effects of test agents in vivo].
    Sato K; Tomioka H
    Kekkaku; 1999 Jan; 74(1):63-70. PubMed ID: 10067057
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activity of KRM 1648 or rifabutin alone or in combination with clarithromycin against Mycobacterium avium complex in human alveolar macrophages.
    Suzuki K; Tsuyuguchi K; Matsumoto H; Yamamoto T; Hashimoto T; Tanaka E; Amitani R; Kuze F
    Int J Tuberc Lung Dis; 1997 Oct; 1(5):460-7. PubMed ID: 9441102
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship between antimycobacterial activities of rifampicin, rifabutin and KRM-1648 and rpoB mutations of Mycobacterium tuberculosis.
    Yang B; Koga H; Ohno H; Ogawa K; Fukuda M; Hirakata Y; Maesaki S; Tomono K; Tashiro T; Kohno S
    J Antimicrob Chemother; 1998 Nov; 42(5):621-8. PubMed ID: 9848446
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [In vitro activities of new rifamycin derivatives against Mycobacterium tuberculosis and M. avium complex].
    Yamamoto T; Amitani R; Kuze F; Suzuki K
    Kekkaku; 1990 Dec; 65(12):805-10. PubMed ID: 2127615
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Current status and perspectives on the development of rifamycin derivative antibiotics].
    Hidaka T
    Kekkaku; 1999 Jan; 74(1):53-61. PubMed ID: 10067056
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Antimycobacterial activities of rifamycin derivatives].
    Kuze F
    Kekkaku; 1991 Oct; 66(10):679-85. PubMed ID: 1960916
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Analysis of the antimycobacterial activities of rifabutin and the relationship between drug-resistance and rpoB mutations of Mycobacterium tuberculosis].
    Han XQ; Huang HR; Li YJ; Yu X; Gao JT; Bi ZQ; Chu NH; Li L; Ma Y
    Zhonghua Jie He He Hu Xi Za Zhi; 2011 Oct; 34(10):762-5. PubMed ID: 22321711
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Cross-resistance between rifampicin and rifabutin among multi-drug resistant Mycobacterium tuberculosis strains].
    Chikamatsu K; Mizuno K; Yamada H; Mitarai S
    Kekkaku; 2009 Sep; 84(9):631-3. PubMed ID: 19860266
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro activity of the benzoxazinorifamycin KRM-1648 against drug-susceptible and multidrug-resistant tubercle bacilli.
    Luna-Herrera J; Reddy MV; Gangadharam PR
    Antimicrob Agents Chemother; 1995 Feb; 39(2):440-4. PubMed ID: 7726512
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [MICs and MBCs of levofloxacin, clarithromycin, and KRM-1648 for Mycobacterium tuberculosis and M. avium complex residing in MONO-MAC-6 human macrophage-like cell and A-549 human type II alveolar epithelial cell lines].
    Sato K; Ogasawara K; Akaki T; Tomioka H
    Kekkaku; 1999 Jul; 74(7):571-7. PubMed ID: 10481412
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In-vitro activity of rifabutin against rifampicin-resistant Mycobacterium tuberculosis isolates with known rpoB mutations.
    Cavusoglu C; Karaca-Derici Y; Bilgic A
    Clin Microbiol Infect; 2004 Jul; 10(7):662-5. PubMed ID: 15214882
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bacteriostatic and bactericidal activities of benzoxazinorifamycin KRM-1648 against Mycobacterium tuberculosis and Mycobacterium avium in human macrophages.
    Mor N; Simon B; Heifets L
    Antimicrob Agents Chemother; 1996 Jun; 40(6):1482-5. PubMed ID: 8726023
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro and in vivo activities of KRM-1648, a newly synthesized benzoxazinorifamycin, against Mycobacterium marinum.
    Yamamoto Y; Saito H; Tomioka H; Sato K; Yamane T; Yamashita K; Hosoe K; Hidaka T
    Zentralbl Bakteriol; 1992 Jul; 277(2):204-9. PubMed ID: 1520979
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cross-resistance between rifampicin and KRM-1648 is associated with specific rpoB alleles in Mycobacterium tuberculosis.
    Park YK; Kim BJ; Ryu S; Kook YH; Choe YK; Bai GH; Kim SJ
    Int J Tuberc Lung Dis; 2002 Feb; 6(2):166-70. PubMed ID: 11931418
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [In vivo activities of benzoxazinorifamycin KRM-1648, clarithromycin, and levofloxacin, or combination of KRM-1648 with diclofenac sodium against Mycobacterium avium infection induced in mice].
    Akaki T; Sato K; Shimizu T; Tomioka H; Kawahara S
    Kekkaku; 1997 Aug; 72(8):491-7. PubMed ID: 9293712
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo susceptibility of Mycobacterium ulcerans to KRM-1648, a new benzoxazinorifamycin, in comparison with rifampicin. Anti-mycobacterial activity of KRM-1648.
    Dhople AM
    Arzneimittelforschung; 2001; 51(6):501-5. PubMed ID: 11455683
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.